Clinical trial · Observational
Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are: * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. * How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients Participants will be asked to answer the question about: * the severity and duration of COVID-19 symptoms * the date of diagnosis of COVID-19 * the date of negative nucleic acid test * the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COVID-19 | — | UNRESOLVED | — |
| Tumor | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- A
- description
- Tumor patients infected with COVID-19
Primary outcomes (2)
- measure
- Incidence of adverse events after antitumor therapy
- timeFrame
- 28 days after antitumor therapy
- description
- Incidence of adverse events after antitumor therapy, including hematologic toxicity,gastrointestinal adverse event, hepatobiliary adverse events, etc.
- measure
- Re-infection of COVID-19
- timeFrame
- 28 days after antitumor therapy
- description
- Antigen testing or nucleic acid testing positive for COVID-19
Secondary outcomes (1)
- measure
- Clinical manifestations of COVID-19 in tumor patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31. * COVID-19 was confirmed by antigen testing or nucleic acid testing. * Tumor was confirmed by pathology. * Patients received systemic antitumor therapy after infected with COVID-19. Exclusion Criteria: * COVID-19 was not confirmed by antigen testing or nucleic acid testing * Tumor was not confirmed by pathology * Patients did not receive systemic antitumor therapy * Patients died before receiving systemic antitumor therapy
References
Publications (0)
Data not yet available